Industry veteran brings expertise to Bioverativ

Tim Harris has been appointed as executive vice president of R&D at Bioverativ (Nasdaq: BIVV), a new company focussed on hemophilia and other rare blood disorders that was spun out of US biotech major Biogen (Nasdaq: BIIB) earlier this year.

Dr Harris brings more than three decades of scientific and leadership expertise to this role where he will be responsible for leading Bioverativ’s scientific direction, advancing pipeline programs and optimizing research and development operations. He will report to John Cox, chief executive of Bioverativ, and be a member of the executive leadership team, effective immediately.

“I am excited to have Tim join the Bioverativ team,” said Mr Cox, adding: “Tim is an innovative and dynamic leader with tremendous scientific expertise across multiple therapeutic areas. He has a proven track record of leading R&D teams that push scientific boundaries, which will be instrumental in helping us rapidly advance our pipeline of novel programs for people with hemophilia, sickle cell disease and other rare blood disorders.”